Moran Wealth Management LLC has acquired 13,654 shares of CRISPR Therapeutics AG, reflecting the rising market confidence in the groundbreaking gene-editing field. The investment, worth approximately $664,000, highlights a continued uptick in institutional backing for CRISPR’s innovative biotech research.

Acadian Asset Management LLC recently took a bold step by expanding its stake in Alkermes plc (NASDAQ:ALKS) to $29.10 million, marking a pronounced 2,422% jump in the first quarter. A recent SEC filing reveals that the institutional investor purchased an additional 846,861 shares, bringing its total to 881,827.

ADAR1 Capital Management LLC has increased its stake in Inhibikase Therapeutics, Inc. by 0.4%, bringing its total holdings to over five million shares. The institutional investor’s move indicates growing confidence in the biotech firm, which now comprises about 2.1% of ADAR1’s portfolio.

ADAR1 Capital Management has significantly raised its stake in Contineum Therapeutics, increasing its shareholding by 105.2% in the first quarter. The purchase brings its total shares in the biotech company to 168,765, valued at approximately $1.18 million.